

Resource Summary Report

Generated by [dkNET](#) on Sep 19, 2026

Brilliant Violet 650(TM) anti-mouse CD45

RRID:AB_2565884

Type: Antibody

Proper Citation

BioLegend Cat# 103151, RRID:AB_2565884

Antibody Information

URL: http://antibodyregistry.org/AB_2565884

Proper Citation: BioLegend Cat# 103151, RRID:AB_2565884

Target Antigen: CD45

Host Organism: rat

Clonality: monoclonal

Comments: Applications: FC

Antibody Name: Brilliant Violet 650(TM) anti-mouse CD45

Description: This monoclonal targets CD45

Target Organism: mouse

Clone ID: Clone 30-F11

Antibody ID: AB_2565884

Vendor: BioLegend

Catalog Number: 103151

Record Creation Time: 20231110T035157+0000

Record Last Update: 20260829T163951+0000

Ratings and Alerts

No rating or validation information has been found for Brilliant Violet 650(TM) anti-mouse CD45.

No alerts have been found for Brilliant Violet 650(TM) anti-mouse CD45.

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 51 mentions in open access literature.

Listed below are recent publications. The full list is available at [dkNET](#) .

Zhang H, et al. (2026) Uncovering spatially resolved functional genomics with CRISPR screen sequencing. *Cell*, 189(15), 4594.

Srinivasan T, et al. (2026) The gut microbiota directs vitamin A flux to regulate intestinal T cell development. *Cell host & microbe*.

Gracia G, et al. (2026) Removal of Interstitial Hyaluronan Facilitates Subcutaneous Administration and Lymphatic Delivery of Anti-CTLA4 and Improves Antitumor Efficacy. *Cancer immunology research*, 14(3), 450.

Wang S, et al. (2026) ENPP1 buffers extracellular cGAMP in brown adipose tissue to limit insulin resistance. *bioRxiv : the preprint server for biology*.

Fercoq F, et al. (2026) Integrin-dependent neutrophil slowing reduces lung perfusion and supports metastasis in a model of breast cancer. *Cell reports*, 45(3), 117101.

Zhu L, et al. (2026) Bach2 antagonizes leukotriene B4-Ltb4r1-JunB signaling to constrain Tfh13 cell differentiation. *Cell reports*, 45(4), 117220.

Butler TD, et al. (2025) Colonic inflammation modulates the intestinal circadian landscape. *iScience*, 28(8), 113183.

Paulishak W, et al. (2025) Bugs delivering drugs: *Listeria monocytogenes*-mediated cytotoxin delivery enhances anti-tumor activity in colorectal cancer. *Cell chemical biology*, 32(12), 1517.

Mulkeen SC, et al. (2025) Reducing Dietary Protein Enhances the Antitumor Effects of Chemotherapy through Immune-Mediated Mechanisms. *Molecular cancer therapeutics*, 24(7), 1099.

Wang Y, et al. (2025) AGO2 mediates immunotherapy failure via suppressing tumor IFN-gamma response-dependent CD8+ T cell immunity. *Cell reports*, 44(4), 115445.

Mooser C, et al. (2025) Diet-derived LPS determines intestinal IgA induction and repertoire characteristics independently of the microbiota. *Immunity*, 58(7), 1778.

Knights AJ, et al. (2025) Synovial macrophage diversity and activation of M-CSF signaling in post-traumatic osteoarthritis. *eLife*, 12.

Knights AJ, et al. (2025) Transcriptomic plasticity of cholinergic adipose macrophages in the acute thermogenic response. *The Journal of biological chemistry*, 301(12), 110925.

Zhao Y, et al. (2025) A Four Amino Acid Intracellular Motif of VISTA Blocks Growth Receptor Signaling in Cancer Cells to Induce Tumor Suppression. *Cancer research*, 85(18), 3399.

Song H, et al. (2025) Targeting tumor monocyte-intrinsic PD-L1 by rewiring STING signaling and enhancing STING agonist therapy. *Cancer cell*, 43(3), 503.

Winsor NJ, et al. (2025) Cross-kingdom-mediated detection of intestinal protozoa through NLRP6. *Cell host & microbe*, 33(3), 388.

Chen ML, et al. (2025) Ketogenic diet inhibits glioma progression by promoting gut microbiota-derived butyrate production. *Cancer cell*.

Shapir Itai Y, et al. (2024) Bispecific dendritic-T cell engager potentiates anti-tumor immunity. *Cell*, 187(2), 375.

Kazer SW, et al. (2024) Primary nasal influenza infection rewires tissue-scale memory response dynamics. *Immunity*, 57(8), 1955.

Strobl K, et al. (2024) JAK-STAT1 as therapeutic target for EGFR deficiency-associated inflammation and scarring alopecia. *EMBO molecular medicine*, 16(12), 3142.